ArticleJournal of computer-aided molecular design2026
From bioactivity prediction to experimental protocol evaluation: QSAR models on the anticarcinogenic activity of flavonoids and related compounds in MCF-7 breast cancer models.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative Structure-Activity Relationships are established in this work to predict the anticarcinogenic activities of flavonoids and related compounds in the MCF-7 breast cancer cell line. The selected descriptors tend to faithfully predict the [Formula: see text] and [Formula: see text] bioactivities, showing a straight-line trend in the correlation with the experimental data, even in this structurally diverse set of molecules. Finally, several structurally related compounds with unknown experimental anticarcinogenic activities are predicted. Therefore, the present study provides a guide for the rational design of potential new therapeutic molecules through the structure-activity parallelisms found. This work also demonstrates that QSAR models lead to evaluating whether the acquisition of experimental data is in agreement with the experimental protocol and methodologies, discriminating based on the domain of applicability and the fit to the QSAR model used.
Indexed as
Identifiers
41910826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.